Izotropic is the only publicly traded company commercializing a dedicated Breast CT imaging platform, known as IzoView, which directly targets a major unmet need in breast cancer care. Unlike traditional mammography, which compresses breast tissue and can miss cancers in women with dense breasts, IzoView produces true 3D volumetric images in about 40 seconds — without compression, pain, or handlingThe company is entering final regulatory and pivotal clinical stages, with an FDA-aligned study in preparation and ongoing site partnerships for clinical deployment.early and accurate detection of breast cancer. As global incidence continues to climb, with millions of new cases each year, traditional imaging technologies often fail to identify tumors—particularly in women with dense breast tissue. Izotropic is pioneering a breakthrough approach through its proprietary 3D breast imaging technology, designed to deliver unparalleled precision, clarity, and diagnostic confidence. By enabling physicians to see cancers earlier and more accurately than ever before, Izotropic has the potential to save countless lives, reduce unnecessary biopsies, and transform patient care. Beyond individual outcomes, its innovation represents a major leap forward in healthcare equity, ensuring that all women—regardless of breast density—can access the most effective diagnostic tools available. In doing so, Izotropic is setting a new global standard for breast imaging and reshaping the future of cancer detection.
Breast cancer incidence continues to rise, with more than 2.3 million new cases diagnosed globally each year and approximately 315,000 expected in the United States in 2025. 
Why Izotropic's tech is so revolutionary.40 seconds.Fully self-shielded radiation system that fits standard exam rooms.Spatial resolution 100× greater than MRI, offering sub-millimeter clarity.This level of precision translates into an estimated 1.1 to 1.25 years of earlier detection, offering a critical diagnostic advantage over standard imaging methods. Early detection is vital, as even a 10% delay in identifying cancer can reduce survival rates by more than 10%. In terms of performance, the technology delivers superior visualization of both malignant and benign lesions when compared to digital breast tomosynthesis (DBT) or MRI, representing a significant leap forward in diagnostic accuracy and patient outcomes.
This simplicity not only reduces infrastructure and operational costs but also makes the system easier to implement across a wide range of healthcare settings. Its design is well-suited for broad adoption in clinics and imaging centers seeking to improve workflow efficiency while integrating AI-driven diagnostic tools, making it an ideal solution for institutions aiming to enhance precision imaging without increasing complexity or cost.
first-mover advantage in the dedicated Breast CT category.Proprietary imaging technology licensed from the University of California, Davis.intellectual property position.underserved market driven by regulatory change, patient demand, and AI-integration trends.Read more below.Izotropic is the only publicly traded company commercializing a dedicated Breast CT imaging platform, known as IzoView, which directly targets a major unmet need in breast cancer care. Unlike traditional mammography, which compresses breast tissue and can miss cancers in women with dense breasts, IzoView produces true 3D volumetric images in about 40 seconds — without compression, pain, or handlingThe company is entering final regulatory and pivotal clinical stages, with an FDA-aligned study in preparation and ongoing site partnerships for clinical deployment.early and accurate detection of breast cancer. As global incidence continues to climb, with millions of new cases each year, traditional imaging technologies often fail to identify tumors—particularly in women with dense breast tissue. Izotropic is pioneering a breakthrough approach through its proprietary 3D breast imaging technology, designed to deliver unparalleled precision, clarity, and diagnostic confidence. By enabling physicians to see cancers earlier and more accurately than ever before, Izotropic has the potential to save countless lives, reduce unnecessary biopsies, and transform patient care. Beyond individual outcomes, its innovation represents a major leap forward in healthcare equity, ensuring that all women—regardless of breast density—can access the most effective diagnostic tools available. In doing so, Izotropic is setting a new global standard for breast imaging and reshaping the future of cancer detection.
Breast cancer incidence continues to rise, with more than 2.3 million new cases diagnosed globally each year and approximately 315,000 expected in the United States in 2025. Why Izotropic's tech is so revolutionary.40 seconds.Fully self-shielded radiation system that fits standard exam rooms.Spatial resolution 100× greater than MRI, offering sub-millimeter clarity.This level of precision translates into an estimated 1.1 to 1.25 years of earlier detection, offering a critical diagnostic advantage over standard imaging methods. Early detection is vital, as even a 10% delay in identifying cancer can reduce survival rates by more than 10%. In terms of performance, the technology delivers superior visualization of both malignant and benign lesions when compared to digital breast tomosynthesis (DBT) or MRI, representing a significant leap forward in diagnostic accuracy and patient outcomes.
This simplicity not only reduces infrastructure and operational costs but also makes the system easier to implement across a wide range of healthcare settings. Its design is well-suited for broad adoption in clinics and imaging centers seeking to improve workflow efficiency while integrating AI-driven diagnostic tools, making it an ideal solution for institutions aiming to enhance precision imaging without increasing complexity or cost.
first-mover advantage in the dedicated Breast CT category.Proprietary imaging technology licensed from the University of California, Davis.intellectual property position.underserved market driven by regulatory change, patient demand, and AI-integration trends.Read more below.https://izocorp.com/
https://izocorp.com/investors/presentation/
https://izocorp.com/site/assets/files/6166/izotropic_investor_presentation_breast_ct.pdf
Izotropic is at a pivotal inflection point as it advances its proprietary IzoView Breast CT system into late-stage regulatory and commercial development. accurate and accessible breast cancer detection, particularly in women with dense breast tissue, where conventional mammography often fails. By offering true 3D volumetric imaging without compression, Izotropic eliminates both the discomfort and the diagnostic blind spots associated with 2D mammograms and even advanced digital breast tomosynthesis (DBT).Unlike many early-stage medtech ventures, Izotropic’s platform isn’t conceptual — it’s fully engineered, tested, and validated through years of university-led research at UC Davis, supported by NIH funding and more than 500 peer-reviewed publications. The company’s system has shown superior detection accuracy, identifying tumors as small as 2mm — roughly doubling the spatial precision of traditional methods. This translates into earlier detection by more than a year, improving survival rates and lowering treatment costs. The technology has proven reliable across malignant, benign, and microcalcified lesions, making it broadly applicable across screening and diagnostic workflows.
From a market perspective, Izotropic operates within a rapidly expanding imaging industry, projected to exceed $8.7 billion globally by 2030, with the U.S. segment alone reaching $1.55 billion. Regulatory tailwinds are also accelerating adoption: over 38 U.S. states now mandate supplemental screening coverage for women with dense breasts, and the FDA’s new breast density disclosure rule compels radiologists to inform patients when standard imaging may be insufficient. This creates a perfect convergence of policy, technology, and clinical need — a setting in which IzoView could become a new standard of care.
its pivotal FDA clinical study, initiate site partnerships, and secure pre-sale commitments from early adopters. The company’s strategy emphasizes capital-efficient growth — targeting hospital networks, private imaging centers, and mobile screening units — all of which face rising demand for precision diagnostics and AI-ready imaging data. Because the IzoView system is self-shielded and compact, installation can occur in standard rooms without major construction or specialized safety requirements, drastically reducing deployment barriers.In comparison to market peers such as Hologic, Nanox, iCAD, Butterfly Network, and Lantheus, Izotropic stands out as a pure-play innovator in dedicated breast CT imaging — a niche yet high-growth category poised for disruption. While these peers have achieved valuations in the hundreds of millions to billions on similar technological advances, Izotropic remains relatively undervalued, offering significant asymmetric upside as it progresses toward FDA clearance and commercialization.
proven science, compelling economics, and clear market timing, aligning itself with the global movement toward earlier cancer detection and personalized imaging. For investors, the company represents a rare opportunity to participate in the redefinition of breast imaging — one that merges patient comfort, clinical precision, and commercial scalability in a single transformative platform.Izotropic is at a pivotal inflection point as it advances its proprietary IzoView Breast CT system into late-stage regulatory and commercial development. accurate and accessible breast cancer detection, particularly in women with dense breast tissue, where conventional mammography often fails. By offering true 3D volumetric imaging without compression, Izotropic eliminates both the discomfort and the diagnostic blind spots associated with 2D mammograms and even advanced digital breast tomosynthesis (DBT).Unlike many early-stage medtech ventures, Izotropic’s platform isn’t conceptual — it’s fully engineered, tested, and validated through years of university-led research at UC Davis, supported by NIH funding and more than 500 peer-reviewed publications. The company’s system has shown superior detection accuracy, identifying tumors as small as 2mm — roughly doubling the spatial precision of traditional methods. This translates into earlier detection by more than a year, improving survival rates and lowering treatment costs. The technology has proven reliable across malignant, benign, and microcalcified lesions, making it broadly applicable across screening and diagnostic workflows.
From a market perspective, Izotropic operates within a rapidly expanding imaging industry, projected to exceed $8.7 billion globally by 2030, with the U.S. segment alone reaching $1.55 billion. Regulatory tailwinds are also accelerating adoption: over 38 U.S. states now mandate supplemental screening coverage for women with dense breasts, and the FDA’s new breast density disclosure rule compels radiologists to inform patients when standard imaging may be insufficient. This creates a perfect convergence of policy, technology, and clinical need — a setting in which IzoView could become a new standard of care.
its pivotal FDA clinical study, initiate site partnerships, and secure pre-sale commitments from early adopters. The company’s strategy emphasizes capital-efficient growth — targeting hospital networks, private imaging centers, and mobile screening units — all of which face rising demand for precision diagnostics and AI-ready imaging data. Because the IzoView system is self-shielded and compact, installation can occur in standard rooms without major construction or specialized safety requirements, drastically reducing deployment barriers.In comparison to market peers such as Hologic, Nanox, iCAD, Butterfly Network, and Lantheus, Izotropic stands out as a pure-play innovator in dedicated breast CT imaging — a niche yet high-growth category poised for disruption. While these peers have achieved valuations in the hundreds of millions to billions on similar technological advances, Izotropic remains relatively undervalued, offering significant asymmetric upside as it progresses toward FDA clearance and commercialization.
proven science, compelling economics, and clear market timing, aligning itself with the global movement toward earlier cancer detection and personalized imaging. For investors, the company represents a rare opportunity to participate in the redefinition of breast imaging — one that merges patient comfort, clinical precision, and commercial scalability in a single transformative platform.https://izocorp.com/
https://izocorp.com/investors/presentation/
https://izocorp.com/site/assets/files/6166/izotropic_investor_presentation_breast_ct.pdf
